Philip Morris
Big Deal for Berkley Bugs
Fields
- Author
- White, D.K.
- Area
- WAKEHAM,HELMUT/KAROL SHARPE'S OFFICE
- Type
- NEWS, NEWSPAPER ARTICLE
- Litigation
- Stmn/Produced
- Site
- R37
- Master ID
- 1000229536/9811
Related Documents:- 1000229537-9544
- 1000229545-9550 Brief Synopsis
- 1000229551-9552 Introduction
- 1000229553-9555 Brief History of Cetus Financing
- 1000229556-9557
- 1000229558-9560 Special Note to Investors
- 1000229561-9563 Special Note Regarding Founder's Stock
- 1000229567-9569 Board of Directors
- 1000229575-9580 Achievements of Cetus People
- 1000229581-9599 Present Cetus Activities
- 1000229600-9616 Research Plan
- 1000229617-9619 Patents
- 1000229621-9656 Debenture Purchase Agreement
- 1000229657-9661 the Cetus Story
- 1000229663-9667 Cloning Business: It's Growing Fast It's Growing Fast
- 1000229668 World Roundup
- 1000229669-9670 Latin Drive: Brazil Spends Millions to Put Alcohol in Cars and Save Oil
- 1000229671 Can US Reduce Imports with Gasoline? Some Say Yes, But Officials Are Dubious
- 1000229672-9673 Bacterial Insulin Production Hears Reality
- 1000229674 Business World
- 1000229675-9677 Who Should Play God?
- 1000229678 Schering Plough New York Analysts' Meeting December 7, 1977
- 1000229679 Indiana Standard Labels Purchase Offer Part of Move to Wider Technology Base
- 1000229681 Oil-Less World May Run on Bugs
- 1000229682-9685 Tinkering with Life
- 1000229686-9687 Set for Biology's New Revolution
- 1000229688 Little Black Box of Cetus
- 1000229689-9695 Industry Is Finding More Jobs for Microbes
- 1000229696-9701 Dup of Id 1000229657-9661
- 1000229702-9710 Recombinant Molecular Research at Cetus Corporation
- 1000229711-9715 New Cetus Antibiotic
- 1000229716-9720 Letter to the Shareholders
- 1000229721-9726 Letter to Shareholders
- 1000229727-9728 Letters to the Shareholders
- 1000229729-9730
- 1000229731-9734 Letter to the Shareholders
- 1000229735-9736 Letter to Shareholders
- 1000229737-9749 the Manipulation of Genes
- 1000229750-9770 Microbial Genetics and the Future of the Pharmaceutical Industry
- 1000229771-9774 Recombinant Dna: Fact and Fiction
- 1000229775-9778 Testomony of Ronald E Cape, Phd President, Cetus Corporation, Berkeley, California Before the House Subcommittee on Science, Research and Technology
- 1000229779-9797 Biosystems Poised for Growth
- 1000229798-9805 Testimony of Ronald E. Cape, Ph.D President, Cetus Corporation, Berkley, California Before the Senate Subcommittee on Science, Technology and Space
- 1000229806-9807 Statement of Ronald E. Cape, Ph.D President, Cetus Corporation, Berkeley, California Before A Special Joint Congressional Hearing in Conjunction with Oversight Hearings on Science and Technology Policy the Senate Subcommittee on Science, Technology and Space of the Commerce, Science and Transportation Committee Presiding, Senator Adlai Stevenson, III Washington, Dc
- 1000229808-9811 Statement of Ronald E. Cape, Ph.D. President, Cetus Corporation, Berkeley, California at the Annual Meeting of the American Association for the Advancement of Science Session on Recombinant Dna Public Health and Biomedical Research Policy Washington, D.C.
- Named Organization
- Cetus
- Farley,P
- Standard Oil
- Farley,P
- Request
- Stmn/R1-004
- Stmn/R1-150
- Author (Organization)
- San Francisco Chronicle
- Date Loaded
- 05 Jun 1998
- UCSF Legacy ID
- cgo74e00
Document Images
I N ONE OF THOSE quiet, unpublicized corpo--
rate moves; Standard Oil Co. of Indiana is
making overtures to shareholders of a small and
exotic Berkeley firm whose main products are
sophisticated bugs. .
- The Berkeley firm is Cetus Corp., founded in
the early 1970s by a covey of physicians and '
scientists, including Nobel prize winners. '
' Standard of Indiana is-putting up $5 million
as an investment in a new issue ' of Cetvis
convertible debentures and is offering the
company's limited number of shareholders $12 a
share for their common stock, up to a limit of 12 .
per cent of the outstanding common.
MHE BIG BENEFICIARIES of the Standard of
j llndiana move on Cetus are the Berkeley
'
d
l
,'
''
f
'
ame is it
eve
op-
:
s
MAI:% CLAI:ii to
(~ETUS
vment of a process for speeding the growth of .~
antibiotic producing bugs
~ R'hat this means basically to a lay.man is.
more drugs per bug," Farley said yesterday.
"`f e accelerate the breeding process of mi-
crobes in a laboratory filled with incubators
and technical instruments."
On a long-term basis, Standard of Indiana
obviouslyy views Cetus as an anchor to windward
on the day the world's oil runs out. .
For Cetus is heavily into research on bacteria
and fungi that can replace the chemicals in
petroleum. now used to produce insecticides,
plastics, dyes, wash-and-wear clothes and
hundreds of other commonplace products.
, . ,_. . _
d
/ company s converUble preferred shareholers ~~ BIOLOGICAL REVOLUTION is coming."
; who are being offered ~i0 a share for stock they A ..
; paid ~;100 a share for less than five yeafs ago. Farley says. In the next 30 years or so
-. biology will replace chemistry in importance in
C
g
With the debentures and convertible and an e , y g
preferred stock offer likely to be accepted by the , and produce chemicals of interest to us. w
Cetus holders, Standard Oil of California will end , "Our company is a member of a..ery small
up with a 22 per cent interest, club. There are no more than a dozen companies
namel to row '
d 1 t them do their thin
y
y
the first right of refusal on up to $9 million in er y , ;
any new financing Cetus does over the next "We supply them with a kind of plush
five years. ; hotel, feed them nutrients; keep them warm
deal also calls for the big oil company to have B kele laboratories Farle
_ .s,I
sa
s:
technology growth companies, the Standard A . for the eare and feeding of baeteria in the
, . .
g
h this country." . .
And sinee Cetns is one of the ciassic hi
What does Standard want with a relatively like us worldwide."
small company that grows bugs ? And as for sales-and profits, Farley is as
`"They want to get the benefit of our closed-mouthed as his. researchers: "One of the
re4earch in industrial microbiology," says Dr. benefits of being a vnryy closely-held company,
Peter Farley, Cetus' executive vice president, a, vrith fewer than 100 shareholders, is that we
- venture capital expert w ho w as don't ha-e to talk about that In public " -4rs= `;
sician and
h
-
p
3
s founders~~
' ~`
an
f th
y
~r~ y
e comp
one o
~ ~
* * *
